Pravastatin
- Generic Name
- Pravastatin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H36O7
- CAS Number
- 81093-37-0
- Unique Ingredient Identifier
- KXO2KT9N0G
- Background
Pravastatin is the 6-alpha-hydroxy acid form of mevastatin. Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug. This drug was developed by Sankyo Co. Ltd.; however, the first approved pravastatin product was developed by Bristol Myers...
- Indication
Pravastatin is indicated for primary prevention of coronary events hypercholesterolemic patients without clinical evidence of coronary heart disease. Its use includes the reduction of risk on myocardial infarction, undergoing myocardial revascularization procedures and cardiovascular mortality.
...
- Associated Conditions
- Acute Coronary Events, Cardiovascular Outcomes, Coronary Artery Atherosclerosis, Death, Dysbetalipoproteinemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Hyperlipidemias, Mixed Dyslipidemias, Myocardial Infarction, Myocardial Revascularization, Secondary prevention cardiovascular event, Stroke, Sudden Cardiac Death, Transient Ischemic Attack, Elevation of serum triglyceride levels
- Associated Therapies
- -
Bioequivalence Study of Pravastatin Sodium Tablets 80 mg Under Fed Conditions
- First Posted Date
- 2010-06-17
- Last Posted Date
- 2012-01-13
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 24
- Registration Number
- NCT01146093
Bioequivalence Study of Pravastatin Sodium Tablets 80 mg Under Fasting Conditions
- First Posted Date
- 2010-06-17
- Last Posted Date
- 2010-06-17
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 43
- Registration Number
- NCT01146106
Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2010-03-08
- Last Posted Date
- 2014-04-28
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT01082588
- Locations
- 🇺🇸
Freedom Trail Clinic, Boston, Massachusetts, United States
Sorafenib Tosylate With or Without Pravastatin in Treating Patients With Liver Cancer and Cirrhosis
- First Posted Date
- 2010-02-25
- Last Posted Date
- 2020-03-30
- Lead Sponsor
- Federation Francophone de Cancerologie Digestive
- Target Recruit Count
- 323
- Registration Number
- NCT01075555
- Locations
- 🇫🇷
Hopital Du Bocage, Dijon, France
A Study Comparing the Mechanisms of Action of Lifibrol and Pravastatin
- Conditions
- Interventions
- First Posted Date
- 2010-01-27
- Last Posted Date
- 2010-01-27
- Lead Sponsor
- University Hospital, Bonn
- Target Recruit Count
- 18
- Registration Number
- NCT01057654
- Locations
- 🇩🇪
Dept. of Clinical Pharmacology, University of Bonn, Bonn, Germany
Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer
- First Posted Date
- 2009-12-23
- Last Posted Date
- 2011-06-27
- Lead Sponsor
- Hospital Donostia
- Target Recruit Count
- 146
- Registration Number
- NCT01038154
- Locations
- 🇪🇸
Department Gastroenterology. Hospital Donostia, San Sebastián, Guipúzcoa, Spain
Cardiovascular Prevention for Persons With HIV
- Conditions
- Interventions
- First Posted Date
- 2009-09-23
- Last Posted Date
- 2017-11-22
- Lead Sponsor
- Hennepin Healthcare Research Institute
- Target Recruit Count
- 37
- Registration Number
- NCT00982189
- Locations
- 🇺🇸
Hennepin County Medical Center, Minneapolis, Minnesota, United States
A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria
- Conditions
- Interventions
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2019-06-13
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 5
- Registration Number
- NCT00879034
- Locations
- 🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States
Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients
- Conditions
- Interventions
- First Posted Date
- 2009-02-13
- Last Posted Date
- 2011-08-02
- Lead Sponsor
- Ospedale di Circolo - Fondazione Macchi
- Target Recruit Count
- 60
- Registration Number
- NCT00843661
- Locations
- 🇮🇹
Ospedale di Circolo and Fondazione Macchi, Varese, Italy
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 115
- Registration Number
- NCT00840177
- Locations
- 🇺🇸
Cancer Center of Kansas-Independence, Independence, Kansas, United States
🇺🇸Genesee Hematology Oncology PC, Flint, Michigan, United States
🇺🇸Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.